InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR Summit
October 8, 2024

InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR Summit

NanoViricides (NYSE American: NNVC) is a development-stage company that is creating special purpose nanomaterials for antiviral therapy. NanoViricides’ President and Executive Chairman Anil R. Diwan, Ph.D., is expected to present at the Global AMR Summit, the premier forum for anti-microbial resistance (“AMR”), to be held at the Kimpton Marlowe Hotel in Cambridge, MA, on October 9, 2024. Dr. Diwan will discuss the company’s “shape-shifting,” “Trojan Horse” platform technology, which facilitates the delivery of one or more “war-heads” against a pathogen to combat AMR. The technology delivers these “war-heads” directly onto the pathogen without affecting normal host cells, thus reducing toxicity and improving pharmacokinetics.

“The ‘shape-shifting’ nanoviricide(TM) platform technology opens up new avenues for combatting anti-microbial resistance,” said Dr. Diwan. “We have already developed nanoviricide drugs against viruses that promise to combat the problem of viral escape from a drug. We believe this technology can be applied to develop novel anti-microbial drugs in order to solve the AMR problem.”

To view the full press release, visit https://ibn.fm/zZrrE

About NanoViricides Inc.

NanoViricides is a development-stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide(TM) class of drug candidates and the nanoviricide(TM) technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. NanoViricides’ lead drug candidate is NV-387, a broad-spectrum antiviral drug that the company plans to develop as a treatment of RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is currently focused on advancing NV-387 into Phase II human clinical trials. NanoViricides’ other advanced candidate is NV-HHV-1 for the treatment of Shingles. The company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. NV-CoV-2 (“API NV-387”) is the company’s nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is NanoViricides’ other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. For more information about the company, visit www.NanoViricides.com.

NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).